Size | Price | Stock |
---|---|---|
5mg | $144 | In-stock |
10mg | $228 | In-stock |
25mg | $468 | In-stock |
50mg | $744 | In-stock |
100mg | $1320 | In-stock |
200 mg | Get quote | |
500 mg | Get quote | |
We match the lowest price on market. |
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
Cat. No. : | HY-19741 |
M.Wt: | 658.81 |
Formula: | C38H38N6O3S |
Purity: | >98 % |
Solubility: | DMSO : ≥ 50 mg/mL (75.89 mM); H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 80°C) (insoluble); Ethanol : 4 mg/mL (6.07 mM; ultrasonic and warming and heat to 60°C) |
A-1331852 is an orally available BCL-XL selective inhibitor with a Ki of less than 10 pM. IC50 & Target: Ki: less than 10 pM (BCL-XL)[1] In Vitro: A-1331852 selectively disrupts BCL-XL–BIM complexes and induces the hallmarks of apoptosis in BCL-XL–dependent Molt-4 cells with IC50s in the low nanomolar range but does not affect MEF cells lacking BAK or BAX. In CellTiter-Glo cell viability assay, A-1331852 inhibits NCI-H847, NCI-H1417, SET-2, HEL, OCI-M2 with EC50 values of 3, 7, 80, 120 and 100 nM[1]. In Vivo: A-1331852 demonstrates antitumor efficacy in the Molt-4 xenograft model, inducing tumor regressions as a single agent. Additionally, A-1331852 combines with venetoclax to recapitulate the efficacy of navitoclax in the NCI-H1963.FP5 xenograft model of SCLC. A-1331852 significantly inhibits tumor growth in seven subcutaneous xenograft models of solid tumors, including breast cancer, NSCLC, and ovarian cancer[1].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information
Your information is safe with us.